Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (13303)	11/12/2001 11:39:26 AM
From: Paul Senior	Read Replies (1) \| Respond to of 78705

Spekulatius, DNR. ELN. I'll consider adding more DNR if price drops further. I've added a bit to ELN today. While pharma stocks are almost never value plays, ELN looks attractive based on its relative value. That's 'relative' meant in comparing ELN to other large pharmaceutical stocks. (primarily current and forward p/e) Imo, buying stocks based on their relative value like this is very risky. A margin of safety, if it exists, is with the absolute, not the relative. Relative attractiveness is a dangerous seductress. Sometimes though, such buys work. We shall see. Paul Senior